Boston Scientific Stock Plunges 9% to 2-Year Low on Negative Re-evaluation of Watchman FLX Trial Data
Summary
Boston Scientific's stock plummeted 9.1% to a two-year low after investors negatively re-evaluated clinical trial data for its Watchman FLX heart implant. While the company initially announced "highly positive results" from the CHAMPION-AF trial on March 28th, the market is now focusing on a numerically higher rate of ischemic strokes (3.2% vs 2%) in Watchman users compared to blood thinners. This concern overshadowed the device's non-inferiority to blood thinners and reduced bleeding, leading to a significant sell-off. The substantial stock drop indicates that the market perceives a material risk or competitive disadvantage, despite company officials and some analysts remaining optimistic about the overall data. Investors will closely watch for further long-term data, particularly the five-year follow-up on ischemic stroke rates, and any potential impact on Watchman FLX adoption.
At the time of this announcement, BSX was trading at $62.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $93.2B. The 52-week trading range was $61.25 to $109.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.